2025-05-28 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co (LLY), presented in a format suitable for a report, with an emphasis on numbers first and then analysis.

## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **LLY Cumulative Return:** 242.63%
*   **VOO Cumulative Return:** 83.14%
*   **Absolute Spread:** 159.49%
*   **Spread Range:** (Max: 313.1%, Min: -27.6%)
*   **Relative Spread:** 54.9%

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period. The current absolute spread is 159.49%, indicating a substantial outperformance. The relative spread of 54.9% suggests that the current outperformance is positioned roughly in the middle of its historical range relative to the S&P 500.

### Alpha, Beta Analysis

| Year       | CAGR     | MDD    | Alpha  | Beta  | Cap(B) |
| ---------- | -------- | ------ | ------ | ----- | ------ |
| 2015-2017  | 10.0%    | 56.3%  | -19.0% | 0.1   | 67.5   |
| 2016-2018  | 38.0%    | 58.6%  | 20.0%  | -0.1  | 94.9   |
| 2017-2019  | 49.0%    | 58.6%  | 19.0%  | 0.3   | 110.2  |
| 2018-2020  | 51.0%    | 58.6%  | 25.0%  | 0.1   | 144.4  |
| 2019-2021  | 105.0%   | 60.6%  | 50.0%  | 0.3   | 239.8  |
| 2020-2022  | 100.0%   | 65.0%  | 94.0%  | 0.3   | 321.9  |
| 2021-2023  | 139.0%   | 65.0%  | 122.0% | 0.3   | 518.0  |
| 2022-2024  | 156.0%   | 72.2%  | 139.0% | 0.3   | 690.4  |
| 2023-2025  | 92.0%    | 76.8%  | 62.0%  | 0.2   | 651.1  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows a strong upward trend, peaking in the 2022-2024 period at 156.0% before slightly decreasing to 92.0% for the most recent period. This indicates significant growth acceleration in recent years.

*   **MDD:** The Maximum Drawdown has been increasing, suggesting higher potential losses from peak to trough. The MDD rose from 56.3% in 2015-2017 to 76.8% in 2023-2025, indicating increased volatility or risk.

*   **Alpha:** Alpha consistently shows positive values, especially in recent periods, indicating that the stock has outperformed its benchmark (S&P 500) even after accounting for market risk. The most recent period (2023-2025) has an Alpha of 62.0%.

*   **Beta:** Beta values are generally low (around 0.1 to 0.3), indicating that the stock is less sensitive to market movements compared to the S&P 500.

*   **Cap(B):** The Market Capitalization has significantly increased over time, showing the company's growth in value.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   **Current Price:** 725.22
*   **Previous Close:** 713.71
*   **Change:** 1.61
*   **5-Day Moving Average:** 725.218
*   **20-Day Moving Average:** 766.4686
*   **60-Day Moving Average:** 801.2517

**Analysis:**

The current price is slightly above the 5-day moving average, but below the 20-day and 60-day moving averages. This suggests a short-term stabilization or slight upward trend, but potential resistance from longer-term moving averages. The recent positive change relative to the previous close indicates some positive momentum.

### 3. Market Risk Indicators and Expected Return

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 38.10
*   **PPO:** -0.5114
*   **Delta_Previous_Relative_Divergence (20-day):** -0.9
*   **Expected Return:** 126.9%

**Analysis:**

*   **MRI:** A low MRI of 0.366 indicates a generally low-risk market environment for LLY.
*   **RSI:** An RSI of 38.10 suggests that the stock is not currently overbought or oversold, leaning slightly towards the oversold territory.
*   **PPO:** A negative PPO (-0.5114) suggests that the stock price is trading slightly below its moving averages, indicating a possible downtrend.
*   **Delta_Previous_Relative_Divergence:** A negative change in relative divergence (-0.9) points to a recent short-term decline in performance relative to its benchmark.
*   **Expected Return:** The high expected return of 126.9% suggests significant potential upside over the long term (2+ years) compared to the S&P 500.

**Hybrid Signal:** The hybrid signal recommends a cash position of 69%, indicating a cautious approach due to market conditions. The signal suggests selling 69.8% of holdings (397 shares).

### 4. Recent News & Significant Events

*   **[2025-05-28]:** Eli Lilly and Co (LLY) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-05-27]:** Analysts are discussing Eli Lilly and Co's (LLY) recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-05-25]:** Eli Lilly and Co (LLY)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-05-24]:** Market experts highlight both risks and opportunities for Eli Lilly and Co (LLY), advising investors to monitor recent news and company announcements.

**Analysis:**

Recent news indicates that LLY has been subject to significant business developments, regulatory changes, or market events, and analysts are closely monitoring its performance. The stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
| ---------- | ---- | ---------- |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2024-04-30 | 2.49 | 8.77 B$   |
| 2025-05-01 | 2.49 | 8.77 B$   |

**Analysis:**

The earnings data reveals the following:

*   **EPS (Earnings Per Share):** EPS values have varied over the last few quarters. The most recent EPS of 3.07 is relatively high.
*   **Revenue:** Revenue has generally increased over the quarters, with the most recent quarter reporting 12.73 B$.

This suggests strong recent performance in both earnings and revenue.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | ------------- |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |
| 2024-06-30   | $11.30B   | 80.80%        |
| 2024-03-31   | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| ------------ | --------- | --------- |
| 2025-03-31   | $15.76B   | 17.50%    |
| 2024-12-31   | $14.19B   | 31.07%    |
| 2024-09-30   | $14.24B   | 6.81%     |
| 2024-06-30   | $13.56B   | 21.88%    |
| 2024-03-31   | $12.81B   | 17.51%    |

**Analysis:**

*   **Revenue & Profit Margin:** Revenue has shown strong growth, and the profit margin has remained consistently high, indicating efficient operations.
*   **Equity & ROE:** Equity has increased over time. The ROE (Return on Equity) fluctuates, with a notable peak in 2024-12-31, suggesting varying levels of profitability relative to equity.

### 7. 종합 Analysis

**Summary:**

Eli Lilly and Co (LLY) has demonstrated significant outperformance compared to the S&P 500, driven by strong revenue and EPS growth. Financial health is robust, with consistently high-profit margins and increasing equity. Despite positive long-term expectations, there are short-term cautionary signals, including a negative divergence from its benchmark and a hybrid signal recommending a high cash position. Recent news indicates that LLY has been subject to significant business developments, regulatory changes, or market events, and analysts are closely monitoring its performance.

**Investment Recommendation:**

Given the data, a mixed strategy is advised. For long-term investors, LLY presents a compelling opportunity due to its strong growth and high expected returns. However, the short-term cautionary signals suggest a need for careful monitoring of market conditions and news. The hybrid signal's recommendation for a high cash position should be taken into account.
